Trial Search Results

Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination

This study investigates a new formulation of paclitaxel (sold as Taxol), known as paclitaxel injection concentrate for nano-dispersion (PICN). This study is currently enrolling in Part A- 2, for patients with cholangiocarcinoma, a type of cancer that starts in the bile ducts or other biliary tract tissues. This is primarily a phase 1, safety, toxicity, and pharmacokinetic (drug levels) study.

Stanford is currently not accepting patients for this trial.

Stanford Investigator(s):

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting